Published in Neurotherapeutics on October 01, 2015
Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders. Br J Pharmacol (2017) 0.79
Intentional cannabis use to reduce crack cocaine use in a Canadian setting: A longitudinal analysis. Addict Behav (2017) 0.75
Overlapping Mechanisms of Stress-Induced Relapse to Opioid Use Disorder and Chronic Pain: Clinical Implications. Front Psychiatry (2016) 0.75
Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. Arch Gen Psychiatry (2006) 3.55
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol (2007) 3.16
Real-time electronic diary reports of cue exposure and mood in the hours before cocaine and heroin craving and use. Arch Gen Psychiatry (2009) 2.95
Cannabidiol--recent advances. Chem Biodivers (2007) 2.89
Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med (2008) 2.60
Potency trends of Δ9-THC and other cannabinoids in confiscated cannabis preparations from 1993 to 2008. J Forensic Sci (2010) 2.56
Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A (1998) 2.48
Glutamate release in the nucleus accumbens core is necessary for heroin seeking. J Neurosci (2008) 2.25
Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol (2001) 2.15
The National Treatment Outcome Research Study (NTORS): 4-5 year follow-up results. Addiction (2003) 2.14
Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci (2005) 2.13
Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiatry (2010) 2.08
Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia (2014) 1.97
The neurobiology of cocaine addiction. Sci Pract Perspect (2005) 1.90
Brain cannabinoid CB₂ receptors modulate cocaine's actions in mice. Nat Neurosci (2011) 1.88
Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. Br J Pharmacol (2007) 1.85
Cannabidiol potentiates Δ⁹-tetrahydrocannabinol (THC) behavioural effects and alters THC pharmacokinetics during acute and chronic treatment in adolescent rats. Psychopharmacology (Berl) (2011) 1.84
Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry (2009) 1.69
Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. J Neurosci (2001) 1.63
Cocaine craving and use during daily life. Psychopharmacology (Berl) (2009) 1.62
Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. Cochrane Database Syst Rev (2007) 1.59
Glutamate and reinstatement. Curr Opin Pharmacol (2009) 1.59
Enhanced sensitivity to stress and drug/alcohol craving in abstinent cocaine-dependent individuals compared to social drinkers. Neuropsychopharmacology (2007) 1.57
Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology (Berl) (1982) 1.56
Agonistic properties of cannabidiol at 5-HT1a receptors. Neurochem Res (2005) 1.54
Craving predicts time to cocaine relapse: further validation of the Now and Brief versions of the cocaine craving questionnaire. Drug Alcohol Depend (2007) 1.54
TRPV2 is activated by cannabidiol and mediates CGRP release in cultured rat dorsal root ganglion neurons. J Neurosci (2008) 1.49
Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A (2006) 1.41
Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology (2011) 1.41
Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol (2010) 1.31
Daily life hour by hour, with and without cocaine: an ecological momentary assessment study. Psychopharmacology (Berl) (2010) 1.21
Cannabidiol attenuates the appetitive effects of Delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology (2010) 1.19
Involvement of 5HT1A receptors in the anxiolytic-like effects of cannabidiol injected into the dorsolateral periaqueductal gray of rats. Psychopharmacology (Berl) (2008) 1.19
Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity. J Pharmacol Exp Ther (2005) 1.18
Cannabidiol is an allosteric modulator at mu- and delta-opioid receptors. Naunyn Schmiedebergs Arch Pharmacol (2006) 1.17
Antipsychotic effect of cannabidiol. J Clin Psychiatry (1995) 1.13
Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci U S A (2014) 1.13
Modulation of effective connectivity during emotional processing by Delta 9-tetrahydrocannabinol and cannabidiol. Int J Neuropsychopharmacol (2009) 1.12
Cocaine craving as a predictor of treatment attrition and outcomes after residential treatment for cocaine dependence. J Stud Alcohol Drugs (2007) 1.12
Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology (Berl) (1990) 1.11
Effects of cannabidiol (CBD) on regional cerebral blood flow. Neuropsychopharmacology (2004) 1.10
Antidepressant-like effects of cannabidiol in mice: possible involvement of 5-HT1A receptors. Br J Pharmacol (2009) 1.08
Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol (2006) 1.08
Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. J Neurosci (2009) 1.05
A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol (2009) 1.03
Anxiolytic-like effect of cannabidiol in the rat Vogel conflict test. Prog Neuropsychopharmacol Biol Psychiatry (2006) 1.03
Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology (Berl) (2004) 1.01
Vaccine for cocaine dependence: a randomized double-blind placebo-controlled efficacy trial. Drug Alcohol Depend (2014) 1.01
Plasma and brain pharmacokinetic profile of cannabidiol (CBD), cannabidivarine (CBDV), Δ⁹-tetrahydrocannabivarin (THCV) and cannabigerol (CBG) in rats and mice following oral and intraperitoneal administration and CBD action on obsessive-compulsive behaviour. Psychopharmacology (Berl) (2011) 1.00
Anticonvulsants for cocaine dependence. Cochrane Database Syst Rev (2008) 0.97
Antidepressants for cocaine dependence. Cochrane Database Syst Rev (2003) 0.97
Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend (2008) 0.96
Cannabidiol improves brain and liver function in a fulminant hepatic failure-induced model of hepatic encephalopathy in mice. Br J Pharmacol (2011) 0.96
The case for assessing cannabidiol in epilepsy. Epilepsia (2014) 0.96
Cannabidiol injected into the bed nucleus of the stria terminalis reduces the expression of contextual fear conditioning via 5-HT1A receptors. J Psychopharmacol (2010) 0.95
Antidepressant-like effect of delta9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav (2010) 0.94
Anxiolytic effect of cannabidiol derivatives in the elevated plus-maze. Gen Pharmacol (1994) 0.94
Cannabidiol ameliorates cognitive and motor impairments in bile-duct ligated mice via 5-HT1A receptor activation. Br J Pharmacol (2010) 0.93
Intra-dorsal periaqueductal gray administration of cannabidiol blocks panic-like response by activating 5-HT1A receptors. Behav Brain Res (2010) 0.89
Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev Bras Psiquiatr (2012) 0.89
Cannabidiol inhibitory effect on marble-burying behaviour: involvement of CB1 receptors. Behav Pharmacol (2010) 0.87
Adjuvants for vaccines to drugs of abuse and addiction. Vaccine (2014) 0.87
Cannabidiol inhibits the reward-facilitating effect of morphine: involvement of 5-HT1A receptors in the dorsal raphe nucleus. Addict Biol (2012) 0.86
Effect of some cannabinoids on naloxone-precipitated abstinence in morphine-dependent mice. Psychopharmacology (Berl) (1976) 0.86
Antipsychotic medications for cocaine dependence. Cochrane Database Syst Rev (2007) 0.85
A systematic review of the antipsychotic properties of cannabidiol in humans. Schizophr Res (2015) 0.85
The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.84
Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture. Brain Res (2010) 0.83
Effect of cytochrome P450 inducers on cocaine-mediated hepatotoxicity. Toxicol Appl Pharmacol (1998) 0.82
Cannabidiol injected into the bed nucleus of the stria terminalis modulates baroreflex activity through 5-HT1A receptors. Pharmacol Res (2010) 0.81
The quasi-morphine withdrawal syndrome: effect of cannabinol, cannabidiol and tetrahydrocannabinol. Pharmacol Biochem Behav (1985) 0.81
Effects and interactions of natural cannabinoids on the isolated heart. Proc Soc Exp Biol Med (1985) 0.80
Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med (2015) 0.79
Anti-aversive effects of cannabidiol on innate fear-induced behaviors evoked by an ethological model of panic attacks based on a prey vs the wild snake Epicrates cenchria crassus confrontation paradigm. Neuropsychopharmacology (2011) 0.79
Cannabinoids inhibit the synaptic uptake of adenosine and dopamine in the rat and mouse striatum. Eur J Pharmacol (2011) 0.79
Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings. Addict Behav (2013) 0.79
Effects of intracisternal administration of cannabidiol on the cardiovascular and behavioral responses to acute restraint stress. Pharmacol Biochem Behav (2011) 0.79
Differential effect of cannabinol and cannabidiol on THC-induced responses during abstinence in morphine-dependent rats. Res Commun Chem Pathol Pharmacol (1975) 0.78
Memory-rescuing effects of cannabidiol in an animal model of cognitive impairment relevant to neurodegenerative disorders. Psychopharmacology (Berl) (2011) 0.78
Interactions between cannabidiol and delta9-THC during abstinence in morphine-dependent rats. Life Sci (1975) 0.78
Cannabidiol was ineffective for manic episode of bipolar affective disorder. J Psychopharmacol (2008) 0.78
[Antagonistic effects of two natural cannabinoids on the isolated heart]. C R Seances Acad Sci III (1983) 0.76